DIAGENODE
ActiveSummary
DIAGENODE has been active since 2003 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €8.7m and a net result of -€3.0m. Equity is shrinking by ~3.1% per year across the filed fiscal years. Its solvency ranks better than 42% of 196 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability1▼-75
Solvency66▼-13
Growth29▼-2
Track record100
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €470,000 at 30 days acceptable
Liquidity tight (current ratio 1.48 against 2.14 in 2024; short-term debt: 40.7% and cash: 5.8% of total assets), and 58.7% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
41.3%
Return on assets
-14%
Age of the figures
12 mo
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 02-03-2026, 59 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
59 d early
2024
6 d early
2023
55 d early
2022
47 d early
2021
31 d early
2020
32 d early
2019
51 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 40 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today. Usually files around 11 March (3 of the last 4 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
30-09-2026 close30-09-2026 today30-04-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Staff and payroll costs Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
In the rankings
#2 employer in the province of Liège, Research and development sector#5 company by total assets in Seraing, Professional and technical services sector#6 company by equity in Seraing, Professional and technical services sector
Turnover
€11.9m▼ 9.1%
2024 · €13.1m
EBIT margin
-21.2%▼ 23.4pp
2024 · 2.3%
Net result
-€3.0m
2024 · €90,613
Working capital
€4.1m▼ 39.0%
2024 · €6.7m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Turnover€28.8m▲ 113%€32.6m▲ 13.3%€13.3m▼ 59.1%€13.1m▼ 2.2%€11.9m▼ 9.1%
Operating result€2.1m-€4.8m€1.7m€295,278▼ 82.4%-€2.5m
Net result€4.1mabove the sector's middle half-€3.4mbelow the sector's middle half€1.6mabove the sector's middle half€90,613within the sector's middle half▼ 94.2%-€3.0mbelow the sector's middle half
EBIT margin7.3%▲ 22.1pp-14.8%▼ 22.0pp12.6%▲ 27.3pp2.3%▼ 10.3pp-21.2%▼ 23.4pp
Equity€15.5mabove the sector's middle half▲ 34.5%€11.4mabove the sector's middle half▼ 26.3%€12.4mabove the sector's middle half▲ 8.6%€12.0mabove the sector's middle half▼ 3.1%€8.7mabove the sector's middle half▼ 27.6%
Total assets€34.2mabove the sector's middle half▲ 35.0%€22.0mabove the sector's middle half▼ 35.5%€31.6mabove the sector's middle half▲ 43.5%€22.3mabove the sector's middle half▼ 29.3%€21.1mabove the sector's middle half▼ 5.7%
Debt€18.6m▲ 35.4%€10.5m▼ 43.3%€18.8m▲ 78.6%€10.3m▼ 45.4%€12.3m▲ 19.4%
Working capital€8.4mabove the sector's middle half▲ 30.2%€3.7mabove the sector's middle half▼ 56.2%€6.3mabove the sector's middle half▲ 69.9%€6.7mabove the sector's middle half▲ 6.8%€4.1mwithin the sector's middle half▼ 39.0%
Solvency45.4%within the sector's middle half▼ 0.2pp51.8%within the sector's middle half▲ 6.4pp39.2%within the sector's middle half▼ 12.6pp53.8%within the sector's middle half▲ 14.6pp41.3%within the sector's middle half▼ 12.5pp
Current ratio1.71within the sector's middle half▼ 0.521.73within the sector's middle half▲ 0.021.45within the sector's middle half▼ 0.282.14within the sector's middle half▲ 0.691.48within the sector's middle half▼ 0.66
Return on assets (ROA)11.9%above the sector's middle half▲ 15.5pp-15.5%below the sector's middle half▼ 27.4pp4.9%within the sector's middle half▲ 20.4pp0.4%within the sector's middle half▼ 4.5pp-14.0%below the sector's middle half▼ 14.4pp
Staff (FTE)101.6above the sector's middle half▲ 16.0%109.6above the sector's middle half▲ 7.9%105above the sector's middle half▼ 4.2%100.8above the sector's middle half▼ 4.0%100.5above the sector's middle half▼ 0.3%
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2023 Turnover -59% on 2022. The previous fiscal year ran 18 months, this one 12.
Result per fiscal year
Operating resultNet result
The operating result turns negative in 2025: a loss of €2.5m after €295,278 in 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €21.1m
Fixed assets
€8.4m ▼ 13.9%
Current assets
€12.7m ▲ 0.6%
Equity and liabilities €21.1m
Equity
€8.7m ▼ 27.6%
Provisions
€94,879 ▲ 64.1%
Debt
€12.3m ▲ 19.4%
Debt's share of the balance-sheet total rises from 46.0% to 58.2%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
-€761,770▼
2024 · €2.3m
Cash flow
-€1.2m▼
2024 · €2.1m
Quick ratio
0.99▼
2024 · 1.33
Debt to equity
1.41▲
2024 · 0.85
ROE
-33.9%▼
2024 · 0.8%
Interest coverage
-3.90▼
2024 · 5.95
Debt ≤ 1 year
€8.6m▲
2024 · €5.9m
Debt > 1 year
€3.4m▼
2024 · €4.0m
Income taxes
€511,235▲
2024 · €22,921
Staff costs
€9.9m▲
2024 · €9.4m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 147 companies that looked in July 2024 the way this one looks now, 2.0% went bankrupt within 24 months and 92% are still going.
- Medium-sized
- solvency 30% or more
- a loss of 10% of the balance sheet or more
- without age
2.0%
went bankrupt
5.4%
stopped otherwise
92%
still going
A further 0.7% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.2% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 147 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Operating income70/76A | €32.8m | €34.6m | €26.1m | €24.2m | €22.4m | ▼ 7.7% |
| Turnover70 | €28.8m | €32.6m | €13.3m | €13.1m | €11.9m | ▼ 9.1% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | €442,467 | -€2.5m | €185,339 | €1.4m | €443,669 | ▼ 68.4% |
| Own construction capitalised72 | €2.3m | €1.3m | €203,888 | - | - | - |
| Other operating income74 | €1.3m | €1.8m | €12.4m | €9.8m | €10.1m | ▲ 2.9% |
| Non-recurring operating income76A | €700 | €1.3m | - | - | - | - |
| Operating charges60/66A | €30.7m | €39.4m | €24.4m | €23.9m | €24.9m | ▲ 3.9% |
| Goods for resale, raw materials and consumables60 | €10.2m | €13.2m | €5.9m | €7.1m | €6.4m | ▼ 9.4% |
| Purchases600/8 | - | - | €6.6m | €7.2m | €5.7m | ▼ 21.0% |
| Change in stocks: decrease (increase)609 | -€924,984 | €1.7m | -€696,856 | -€111,869 | €737,517 | ▲ 759% |
| Services and other goods61 | €9.7m | €8.1m | €4.8m | €4.3m | €4.5m | ▲ 3.6% |
| Remuneration, social security and pensions62 | €7.3m | €12.9m | €9.6m | €9.4m | €9.9m | ▲ 4.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €3.0m | €3.6m | €2.3m | €2.0m | €1.7m | ▼ 12.8% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | €212,891 | €226,282 | €22,596 | €242,761 | €560,485 | ▲ 131% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | -€18,437 | -€2,402 | €306,400 | -€306,400 | €61,649 | ▲ 120% |
| Other operating charges640/8 | €238,649 | €250,068 | €1.6m | €1.1m | €1.7m | ▲ 49.9% |
| Non-recurring operating charges66A | - | €1.0m | - | €2,477 | - | - |
| Operating profit (loss)9901 | €2.1m | -€4.8m | €1.7m | €295,278 | -€2.5m | ▼ 951% |
| Financial income75/76B | - | - | €876,881 | €570,813 | €502,812 | ▼ 11.9% |
| Recurring financial income75 | €1.5m | €1.7m | €876,881 | €570,813 | €502,812 | ▼ 11.9% |
| Income from financial fixed assets750 | - | - | - | €19,302 | €0 | ▼ 100% |
| Income from current assets751 | €6,472 | €6,204 | €15,398 | €629 | €0 | ▼ 100% |
| Other financial income752/9 | €1.5m | €1.7m | €861,482 | €550,883 | €502,812 | ▼ 8.7% |
| Financial charges65/66B | €405,709 | €541,967 | €1.1m | €778,941 | €458,347 | ▼ 41.2% |
| Recurring financial charges65 | €405,709 | €541,967 | €613,383 | €762,325 | €458,347 | ▼ 39.9% |
| Debt charges650 | €220,064 | €301,801 | €350,953 | €386,815 | €195,175 | ▼ 49.5% |
| Write-downs on current assets other than stocks, contracts in progress and trade receivables: additions (reversals)651 | €10,566 | - | - | - | €0 | - |
| Other financial charges652/9 | €175,079 | €240,166 | €262,430 | €375,510 | €263,172 | ▼ 29.9% |
| Non-recurring financial charges66B | - | - | €521,349 | €16,616 | - | - |
| Profit (loss) for the period before taxes9903 | €3.2m | -€3.6m | €1.4m | €87,151 | -€2.5m | ▼ 2,931% |
| Transfer from deferred taxes780 | €182,096 | €157,137 | €47,514 | €26,383 | €24,601 | ▼ 6.8% |
| Income taxes67/77 | -€720,924 | -€73,685 | -€86,779 | €22,921 | €511,235 | ▲ 2,130% |
| Taxes670/3 | €49,209 | €15,295 | €25,828 | €75,909 | €554,187 | ▲ 630% |
| Tax adjustments and reversals of tax provisions77 | €770,133 | €88,980 | €112,607 | €52,988 | €42,951 | ▼ 18.9% |
| Profit (loss) for the period9904 | €4.1m | -€3.4m | €1.6m | €90,613 | -€3.0m | ▼ 3,360% |
| Profit (loss) for the period to be appropriated9905 | €4.1m | -€3.4m | €1.6m | €90,613 | -€3.0m | ▼ 3,360% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €34.2m | €22.0m | €31.6m | €22.3m | €21.1m | ▼ 5.7% |
| Formation expenses20 | €10,358 | €2,169 | €185 | €0 | €0 | - |
| Fixed assets21/28 | €13.9m | €13.3m | €11.3m | €9.8m | €8.4m | ▼ 13.9% |
| Intangible fixed assets21 | €3.6m | €2.7m | €1.8m | €1.2m | €690,823 | ▼ 40.7% |
| Tangible fixed assets22/27 | €8.9m | €9.7m | €9.3m | €8.6m | €7.7m | ▼ 9.9% |
| Land and buildings22 | €1.1m | €1.0m | €992,906 | €1.4m | €1.4m | = |
| Plant, machinery and equipment23 | €580,211 | €1.6m | €1.9m | €1.6m | €1.2m | ▼ 24.1% |
| Furniture and vehicles24 | €259,709 | €224,686 | €171,046 | €156,240 | €166,159 | ▲ 6.3% |
| Leasing and similar rights25 | €7.0m | €6.3m | €5.7m | €5.3m | €4.8m | ▼ 9.1% |
| Assets under construction and advance payments27 | €15,750 | €533,747 | €485,541 | €124,755 | €127,755 | ▲ 2.4% |
| Financial fixed assets28 | €1.4m | €872,154 | €243,450 | €34,725 | €4,629 | ▼ 86.7% |
| Affiliated companies280/1 | €1.4m | €867,524 | €238,821 | €30,096 | €0 | ▼ 100% |
| Participating interests280 | €1.1m | €130,289 | €2,616 | €0 | €0 | - |
| Amounts receivable281 | €309,199 | €737,235 | €236,205 | €30,096 | €0 | ▼ 100% |
| Other financial fixed assets284/8 | €3,437 | €4,630 | €4,629 | €4,629 | €4,629 | = |
| Amounts receivable and cash guarantees285/8 | €3,437 | €4,630 | €4,629 | €4,629 | €4,629 | = |
| Current assets29/58 | €20.2m | €8.7m | €20.3m | €12.6m | €12.7m | ▲ 0.6% |
| Stocks and contracts in progress3 | €4.9m | €3.0m | €3.7m | €4.8m | €4.2m | ▼ 11.6% |
| Stocks30/36 | €4.4m | €3.0m | €3.7m | €4.8m | €4.2m | ▼ 11.6% |
| Raw materials and consumables30/31 | €1.2m | €822,466 | €1.4m | €1.8m | €1.6m | ▼ 13.0% |
| Work in progress32 | - | €6,146 | €11,220 | €13,729 | €15,457 | ▲ 12.6% |
| Finished goods33 | €319,960 | €470,487 | €650,752 | €731,569 | €691,775 | ▼ 5.4% |
| Goods purchased for resale34 | €2.7m | €1.2m | €1.4m | €2.1m | €1.7m | ▼ 15.7% |
| Advance payments36 | €166,769 | €575,351 | €265,667 | €123,611 | €171,856 | ▲ 39.0% |
| Contracts in progress37 | €591,055 | - | - | - | - | - |
| Amounts receivable within one year40/41 | €9.9m | €4.4m | €14.0m | €5.7m | €6.8m | ▲ 19.3% |
| Trade receivables40 | €8.2m | €3.1m | €12.5m | €4.8m | €6.1m | ▲ 27.4% |
| Other amounts receivable41 | €1.7m | €1.2m | €1.5m | €916,658 | €707,632 | ▼ 22.8% |
| Current investments50/53 | - | - | - | €2,970 | €2,970 | = |
| Other investments51/53 | - | - | - | €2,970 | €2,970 | = |
| Cash at bank and in hand54/58 | €4.6m | €1.2m | €2.2m | €2.1m | €1.2m | ▼ 41.0% |
| Deferred charges and accrued income490/1 | €730,712 | €116,808 | €410,636 | €98,853 | €472,378 | ▲ 378% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €34.2m | €22.0m | €31.6m | €22.3m | €21.1m | ▼ 5.7% |
| Equity10/15 | €15.5m | €11.4m | €12.4m | €12.0m | €8.7m | ▼ 27.6% |
| Contributions10/11 | €7.2m | €7.2m | €7.2m | €7.2m | €7.2m | = |
| Capital10 | €7.2m | €7.2m | €7.2m | €7.2m | €7.2m | = |
| Issued capital100 | €7.2m | €7.2m | €7.2m | €7.2m | €7.2m | = |
| Reserves13 | €405,764 | €405,765 | €483,439 | €487,969 | €487,969 | = |
| Non-distributable reserves130/1 | €405,764 | €405,765 | €483,439 | €487,969 | €487,969 | = |
| Legal reserve130 | €405,764 | €405,765 | €483,439 | €487,969 | €487,969 | = |
| Profit (loss) carried forward14 | €4.7m | €1.2m | €2.7m | €2.8m | -€155,608 | ▼ 106% |
| Investment grants15 | €3.2m | €2.6m | €2.0m | €1.5m | €1.2m | ▼ 23.7% |
| Provisions and deferred taxes16 | €65,612 | €80,272 | €390,613 | €57,831 | €94,879 | ▲ 64.1% |
| Provisions for liabilities and charges160/5 | €6,497 | €4,094 | €310,495 | €4,095 | €65,744 | ▲ 1,506% |
| Pensions and similar obligations160 | - | - | - | €0 | - | - |
| Environmental obligations163 | €6,497 | €4,094 | €0 | €0 | €0 | - |
| Other liabilities and charges164/5 | - | - | €310,495 | €4,095 | €65,744 | ▲ 1,506% |
| Deferred taxes168 | €59,115 | €76,178 | €80,119 | €53,736 | €29,135 | ▼ 45.8% |
| Amounts payable17/49 | €18.6m | €10.5m | €18.8m | €10.3m | €12.3m | ▲ 19.4% |
| Amounts payable after more than one year17 | €6.3m | €5.3m | €4.7m | €4.0m | €3.4m | ▼ 16.3% |
| Financial debts170/4 | €6.3m | €5.3m | €4.7m | €4.0m | €3.4m | ▼ 16.3% |
| Leasing and similar obligations172 | €6.3m | €5.3m | €4.7m | €4.0m | €3.4m | ▼ 16.3% |
| Amounts payable within one year42/48 | €11.8m | €5.0m | €14.0m | €5.9m | €8.6m | ▲ 45.5% |
| Current portion of amounts payable after more than one year42 | €657,742 | €639,151 | €631,752 | €643,608 | €658,031 | ▲ 2.2% |
| Financial debts43 | - | - | €7.8m | €759,818 | €3.6m | ▲ 377% |
| Other loans439 | - | - | €7.8m | €759,818 | €3.6m | ▲ 377% |
| Trade debts44 | €7.4m | €2.3m | €3.2m | €2.4m | €2.1m | ▼ 14.6% |
| Suppliers440/4 | €7.4m | €2.3m | €3.1m | €2.4m | €2.1m | ▼ 14.6% |
| Bills of exchange payable441 | - | €54,629 | €92,262 | €0 | €0 | - |
| Advances received on contracts in progress46 | €27,597 | - | - | - | - | - |
| Taxes, remuneration and social security45 | €1.0m | €1.9m | €2.1m | €1.9m | €2.2m | ▲ 13.7% |
| Taxes450/3 | €7,325 | €12,413 | €59,490 | €48,438 | €83,889 | ▲ 73.2% |
| Remuneration and social security454/9 | €1.0m | €1.8m | €2.0m | €1.8m | €2.1m | ▲ 12.2% |
| Other amounts payable47/48 | €2.8m | €203,109 | €349,907 | €175,668 | €69,409 | ▼ 60.5% |
| Accrued charges and deferred income492/3 | €497,813 | €189,180 | €132,687 | €350,282 | €322,510 | ▼ 7.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €4.1m | -€3.4m | €1.6m | €90,613 | -€3.0m | ▼ 3,360% |
| + Depreciation and write-downs630 | €3.0m | €3.6m | €2.3m | €2.0m | €1.7m | ▼ 12.8% |
| Operating cash flow (approximation) | €7.1m | €145,621 | €3.9m | €2.1m | -€1.2m | ▼ 157% |
| Investment in fixed assets (approximation) | - | -€3.0m | -€339,444 | -€436,592 | -€394,602 | ▲ 9.6% |
| Change in cash | - | -€3.4m | €951,293 | -€113,741 | -€841,619 | ▼ 640% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
02-03
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
24-04
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
06-03
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
30-09
Financial
Back to profitnet €1.6m
Net result €1.6m after one loss-making year.
14-03
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
30-09
Financial
Weakest financial yearnet -€3.4m
Net result drops to -€3.4m, the lowest in the series; recovery starts the following year.
2021
30-09
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
31-03
Financial
Back to profitnet €4.1m
Net result €4.1m after one loss-making year.
2020
29-09
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2019
10-09
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2018
28-09
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2017
04-10
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2016
20-09
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 24 acts read
About the unread acts
We know of 24 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
24 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Seraing · 1 establishment unit since 2003
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue du Bois St-Jean 34102 Seraing1 establishment unit
DIAGENODE S.A.
since 20032.132.164.126
Structure & network
Owners and holdings
2 owners · 1 holdingChain of control
- HOLOGIC, INC.US
- HOLOGIC
- DIAGENODE
Highest known parent: HOLOGIC, INC. (United States). The sources do not say who stands above it.
Owners 2
- HOLOGICparent100%
- HOLOGIC HUB LTDGBparentSourceLEI registerconsolidated
Holdings 1
-
100%
According to the annual accounts to 30-09-2024 of DIAGENODE and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Public money · subsidies and aid
European research
20 projects · 5,691,069 EUR EU contributionProjects
A BLUEPRINT of Haematopoietic Epigenomes
The regulatory GENomE of SWine and CHicken: functional annotation during development
Predictive Epigenetics: Fusing Theory and Experiment
High Throughput Systematic Single Cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysing, Selecting and Preparing Sequence-ready DNA
Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study
Show 15 more projects
Epigenetic Training Network - Innovative techniques and models to understand epigenetic regulation in the pathogenesis of common diseases
Genomic predictors and oncogenic drivers in hepatocellular carcinoma
The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinical management
AGE-RELATED CHANGES IN HEMATOPOIESIS
Chromatin architecture and Design
Studying Physiology and Pathology of Imprinted Genes to understand the role of Epigenetic Mutations in Human Disease
Chromatin Dynamics in Development and Disease
Epigenetics and System Biology of Stem cells and Reprogramming
Development of Laser-Based Technologies and Prototype Instruments for Genome-Wide Chromatin ImmunoPrecipitation Analyses
Epigenetic regulation of economically important plant traits
Control of metabolic and inflammatory pathways by nuclear receptors
Chromatin diseases: from basic mechanisms to therapy
BovReg - Identification of functionally active genomic features relevant to phenotypic diversity and plasticity in cattle
Aggression in Children: Unraveling gene-environment interplay to inform Treatment and InterventiON strateg
DNA methylation markers to predict treatment success of biologicals in Crohn’s disease.
Recognitions · licences · registrations
Legal Entity Identifier
5493006F0WPPG3MLW903
Similar companies · same sector, comparable size
Intrexon Actobiotics
BE 0882.251.820
Nazareth-De Pinte · Eq €8,592,009
BIOMEDICAL SYSTEMS
BE 0421.984.741
Leuven · Eq €9,055,041
Protealis
BE 0765.251.410
Gent · Eq €9,062,218
Swedish Orphan Biovitrum (Belgium)
BE 0536.217.087
Zaventem · Eq €9,146,158
Enovalife
BE 0503.997.053
Evere · Eq €7,945,947
Of 762 companies in sector 72101 we hold annual accounts for 484. 154 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded30-05-2003
Fiscal year end30-09
Activities, NACEBEL 2025
72101Research and development on biotechnology
26600Manufacture of computer, electronic and optical products
Contact
E-invoicing
Reachable via Peppol
Peppol ID
0208:0480422786
Also
9925:BE0480422786
Registered
26-01-2026
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.